BRIEF published on 04/07/2026 at 07:05, 4 months 18 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 4 months 18 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 5 months 4 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 5 months 4 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 7 months 13 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 8 months 23 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 11 months ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 11 months ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 2 years ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 2 years ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 08/25/2026 at 23:05, 5 hours 14 minutes ago Faraday Copper Shareholders Approve Share Issuance in Connection with the Acquisition of the San Manuel Project
Published on 08/25/2026 at 15:00, 13 hours 19 minutes ago Four Nines Gold Intersects Hydrothermal Breccia in First Three Holes at Hayden Hill
Published on 08/25/2026 at 14:30, 13 hours 49 minutes ago First Breach Completes First Flight of Drone Prototype and Advances American-Made Manufacturing Through Hellbender Agreement
Published on 08/25/2026 at 14:30, 13 hours 49 minutes ago Tintina Mines Completes Strategic Partnership Transaction, Consolidating 100% Ownership of the Dos Amigos (formerly Domeyko Sulfuros) Copper-Gold Project in Chile
Published on 08/26/2026 at 03:58, 20 minutes ago EQS-Adhoc: AUSTRIACARD HOLDINGS AG: DAI NIPPON PRINTING CO., LTD. INTENDS TO PURSUE SQUEEZE-OUT AND DELISTING
Published on 08/26/2026 at 03:15, 1 hour 3 minutes ago Binzhou Unveils 'Trade-In' Housing Models to Stabilize Real Estate Market
Published on 08/25/2026 at 22:35, 5 hours 43 minutes ago ZOOPUNK Makes Its Opening Night Live Debut at gamescom 2026
Published on 08/25/2026 at 20:35, 7 hours 43 minutes ago Michter's Named the #1 Most Admired Whiskey in the World by Drinks International in New 2026 Ranking
Published on 08/25/2026 at 17:45, 10 hours 34 minutes ago CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 08/25/2026 at 17:45, 10 hours 34 minutes ago Imerys-08-2026-information-share-capital-and-voting-rights-as-of-31-July-2026
Published on 08/25/2026 at 08:30, 19 hours 49 minutes ago Eiffage wins several contracts worth a total of €132 million in the healthcare sector
Published on 08/24/2026 at 18:00, 1 day 10 hours ago Outstanding shares and voting rights statement at 31 July 2026
Published on 08/24/2026 at 17:59, 1 day 10 hours ago Saint-Gobain strengthens its positioning in construction chemicals and light construction in Latin America
